Molina J-M, et al. Doravirine (DOR) versus ritonavir-boosted darunavir (DRV+r): 96-week results of the randomized, double-blind, phase 3 DRIVE-FORWARD Noninferiority trial. AIDS 2018.
EASL International Liver Congress (ILC) 2022: virale hepatitis in de spotlights
jul 2022 | Hepatitis, Vaccinatie